Literature DB >> 15102866

Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.

Gary J Noel1, Daniel B Goodman, Shuchean Chien, Bhavna Solanki, Mukund Padmanabhan, Jaya Natarajan.   

Abstract

A clinical trial was conducted in healthy volunteers using both periodic and continuous ECG recordings to assess the effect of increasing doses of levofloxacin on the QT and QTc interval. Periodic and continuous ECGs were recorded before and after subjects were dosed with placebo and increasing doses of levofloxacin (500 mg, 1000 mg, 1500 mg) that included doses twice the maximum recommended dose of 750 mg in a double-blind, randomized, four-period, four-sequence crossover trial. Mean heart rate (HR) and the QT and QTc interval after dosing with levofloxacin and placebo were compared, and HR-QT interval relationships defined by linear regression analysis were calculated. After single doses of 1000 and 1500 mg of levofloxacin, HR increased significantly, as measured by periodic and continuous ECG recordings. This transient increase occurred at times of peak plasma concentration and was without symptoms. Mean QT intervals after placebo and mean intervals after levofloxacin were indistinguishable. Using periodic ECG recordings, single doses of 1500 mg were associated with small increases in QTc that were statistically significant. In contrast, an effect on QTc was shown only using the Bazett formula with data obtained from continuous ECG recordings. Together with the finding that levofloxacin does not influence HR-QT relationships, these findings suggest that levofloxacin has little effect on prolonging ventricular repolarization and that small increases in HR associated with high doses of levofloxacin contribute to the drug's apparent effect on QTc. Single doses of 1000 or 1500 mg of levofloxacin transiently increase HR without affecting the uncorrected QT interval. Differences in mean QTc after levofloxacin compared to placebo vary depending on the correction formula used and whether the data analyzed are from periodic or continuous ECG recordings. This work suggests that using continuous ECG recordings in assessing QT/QTc effects of drugs may be of value, particularly with drugs that might influence HR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102866     DOI: 10.1177/0091270004264643

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  16 in total

1.  Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pages.

Authors:  Atsushi Sugiyama; Yuji Nakamura; Satomi Nishimura; Satomi Adachi-Akahane; Yuji Kumagai; Juleen Gayed; Asif Naseem; Georg Ferber; Jorg Taubel; John Camm
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

2.  In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery.

Authors:  Doris Hutschala; Keso Skhirtladze; Andreas Zuckermann; Wilfried Wisser; Peter Jaksch; Bernhard Xaver Mayer-Helm; Heinz Burgmann; Ernst Wolner; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.

Authors:  Jeffrey S Litwin; Michael S Benedict; Michael D Thorn; Laura E Lawrence; Sue K Cammarata; Eugene Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

4.  A meta-analysis of ECG data from healthy male volunteers: diurnal and intra-subject variability, and implications for planning ECG assessments and statistical analysis in clinical pharmacology studies.

Authors:  R I Harris; S E Steare
Journal:  Eur J Clin Pharmacol       Date:  2006-10-06       Impact factor: 2.953

Review 5.  Safety profile of the fluoroquinolones: focus on levofloxacin.

Authors:  Hans H Liu
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

6.  Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.

Authors:  Jorg Taubel; Asif Naseem; Tomohiko Harada; Duolao Wang; Radivoj Arezina; Ulrike Lorch; A John Camm
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

Review 7.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

Review 8.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

9.  The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study.

Authors:  Doris Hutschala; Christian Kinstner; Keso Skhirtladze; Bernhard-Xaver Mayer-Helm; Markus Zeitlinger; Wilfried Wisser; Markus Müller; Edda Tschernko
Journal:  Intensive Care Med       Date:  2008-05-14       Impact factor: 17.440

10.  Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anthony J Garcia-Prats; Heather R Draper; Lubbe Wiesner; Jana Winckler; Stephanie Thee; Kelly E Dooley; Rada M Savic; Helen M McIlleron; H Simon Schaaf; Anneke C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.